Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Pamela L. Wolters's publication output changed over time?
ScholarIQpublication output · 1991–2025
Output grew0% over the shown period — from 1 works in 1991 to 1 in 2025.
1
1
2
1
2
2
1
1
19912016201720182020202120222025
What are the most-cited papers on Pamela L. Wolters?
ScholarIQmost cited works
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry, Nirali N. Shah, Rimas J. Orentas, Maryalice Stetler‐Stevenson, Constance M. Yuan, Sneha Ramakrishna, Pamela L. Wolters, Staci Martin, Cindy Delbrook, Bonnie Yates, Haneen Shalabi, Thomas J. Fountaine, Jack F. Shern, Robbie G. Majzner, David F. Stroncek, Marianna Sabatino, Yang Feng, Dimiter S. Dimitrov, Ling Zhang, Sang M. Nguyen, Haiying Qin, Boro Dropulić, Daniel W Lee, Crystal L. Mackall
Nature Medicine. 20171,358 Citations
Neurofibromatosis type 1
David H. Gutmann, Rosalie E. Ferner, Robert Listernick, Bruce R. Korf, Pamela L. Wolters, Kimberly Johnson
Nature Reviews Disease Primers. 2017848 Citations
Selumetinib in Children with Inoperable Plexiform Neurofibromas
Andrea M. Gross, Pamela L. Wolters, Eva Dombi, Andrea Baldwin, Patricia Whitcomb, Michael J. Fisher, Brian Weiss, AeRang Kim, Miriam Bornhorst, Amish C. Shah, Staci Martin, Marie Claire Roderick, Dominique C. Pichard, Amanda Carbonell, Scott M. Paul, Janet Therrien, Oxana B. Kapustina, Kara Heisey, D. Wade Clapp, Chi Zhang, Cody J. Peer, William D. Figg, Malcolm A. Smith, John Glod, Jaishri O. Blakeley, Seth M. Steinberg, David Venzon, L. Austin Doyle, Brigitte C. Widemann
New England Journal of Medicine. 2020714 CitationsOPEN ACCESS
Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
Eva Dombi, Andrea Baldwin, Leigh Marcus, Michael J. Fisher, Brian Weiss, AeRang Kim, Patricia Whitcomb, Staci Martin, Lindsey Aschbacher‐Smith, Tilat A. Rizvi, Jianqiang Wu, Rachel Ershler, Pamela L. Wolters, Janet Therrien, John Glod, Jean B. Belasco, Elizabeth K. Schorry, Alessandra Brofferio, Amy J. Starosta, Andrea Gillespie, Austin L. Doyle, Nancy Ratner, Brigitte C. Widemann
New England Journal of Medicine. 2016673 CitationsOPEN ACCESS
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah, Steven L. Highfill, Haneen Shalabi, Bonnie Yates, Jianjian Jin, Pamela L. Wolters, Amanda K. Ombrello, Seth M. Steinberg, Staci Martin, Cindy Delbrook, Leah Hoffman, Lauren Little, Anusha Ponduri, Haiying Qin, Haris Qureshi, Alina Dulau‐Florea, Dalia Salem, Hao‐Wei Wang, Constance M. Yuan, Maryalice Stetler‐Stevenson, Sandhya R. Panch, Minh Tran, Crystal L. Mackall, David F. Stroncek, Terry J. Fry
Journal of Clinical Oncology. 2020421 CitationsOPEN ACCESS
Related on ScholarIQ
National Institutes of Health
Institution
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Paper
Neurofibromatosis type 1
Paper
Selumetinib in Children with Inoperable Plexiform Neurofibromas
Paper
Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
Paper
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Paper